CD274 and gastroesophageal junction adenocarcinoma: Similarly to PANDA, the DANTE trial [21,22] investigated the use of perioperative atezolizumab with chemotherapy in resectable gastric or gastroesophageal junction adenocarcinomas and also had a larger percentage of PD-L1-positive (58%) and MSI-H (8%) patients, showed downstaging benefits (ypT0, 23% vs. 15%, p = 0.044; ypT0-T2, 61% vs. 48%, p = 0.015; ypN0, 68% vs. 54%, p = 0.012).